The clinical value of $[^{18}\text{F}]$fluorodihydroxyphenylalanine positron emission tomography in primary diagnosis, staging, and restaging of neuroendocrine tumors

Saila Kauhanen$^{1,2}$, Marko Seppänen$^{1}$, Jari Ovaska$^{2}$, Heikki Minn$^{1,3}$, Jörgen Bergman$^{4}$, Pirkko Korsoff$^{5}$, Pasi Salmela$^{6}$, Juha Saltevo$^{7}$, Timo Sane$^{8}$, Matti Välimäki$^{8}$ and Pirjo Nuutila$^{1,9}$

$^1$Turku PET Center, Turku University Central Hospital, PO Box 52, FIN-20521 Turku, Finland
$^2$Department of Surgery, Turku University Central Hospital, Turku, Finland
$^3$Department of Oncology and Radiotherapy, Turku University Central Hospital, Turku, Finland
$^4$Radiopharmaceutical Chemistry Laboratory, University of Turku, Turku, Finland
$^5$Department of Medicine, Satakunta Central Hospital, Pori, Finland
$^6$Department of Medicine, Oulu University Central Hospital, Oulu, Finland
$^7$Central Hospital of Middle Finland, Jyväskylä, Finland
$^8$Division of Endocrinology, Department of Medicine, Helsinki University Central Hospital, Helsinki, Finland
$^9$Department of Medicine, Turku University Central Hospital, Turku, Finland

(Correspondence should be addressed to P Nuutila; Email: pirjo.nuutila@tyks.fi)

Abstract

The study was set up to determine the clinical value of dihydroxyphenylalanine positron emission tomography-computed tomography ([$^{18}\text{F}]$DOPA PET-CT) in patients with neuroendocrine tumors (NETs). Eighty-two patients with suspected/known NET were imaged with PET(-CT) using [$^{18}\text{F}]$DOPA. Patients were divided into two groups: primary diagnosis/staging and restaging of disease. All patients without previous diagnosis of NET had biochemical proof of disease. The diagnostic accuracy of PET was assessed by comparing the histopathology and clinical follow-up. The overall accuracy of [$^{18}\text{F}]$DOPA PET was 90%. In patients having PET for primary diagnosis/staging ($n=32$), the accuracy of PET was 88%, and for restaging 92% ($n=61$). The mean $\text{s.d.}$ sizes of primary and metastatic lesions detected by PET were 26±11 and 16±9 mm respectively. In organ-region-specific analysis, the sensitivity and specificity were 100% in the primary diagnosis of pheochromocytoma ($n=16$) and metastases were found in all cases with recurrent disease ($n=5$). The accuracy for NET of gastrointestinal tract was 92% in restaging ($n=24$). For the NETs located in the head–neck–thoracic region ($n=19$), the overall accuracy of PET was 89% including 12 cases of recurrent medullary thyroid cancer with a sensitivity of 90%. In analysis of patients with biochemical proof of disease combined with negative conventional imaging methods, PET had positive and negative predictive value of 92% and 95% respectively. [$^{18}\text{F}]$DOPA PET-CT provided important additional information in the diagnosis of pheochromocytoma and restaging of known NET. Both in primary diagnosis and in patients with formerly known NET and increasing tumor markers, [$^{18}\text{F}]$DOPA PET-CT is a sensitive first-line imaging method.

Endocrine-Related Cancer (2009) 16 255–265

Introduction

Neuroendocrine tumors (NETs) are a heterogeneous group of rare tumors arising from diffuse cells. These tumors are usually relatively slow growing with low malignant potential, but have functional characteristics that can produce pronounced endocrine-related symptoms despite their small size. NETs are located mainly (90%) in the gastrointestinal tract and the pancreas (gastroenteropancreatic NETs). They can also be found in various other sites such as the bronchopulmonary...
system, the adrenal medulla (pheochromocytoma), the extra-adrenal paraganglia (paraganglioma), and the head–neck region (e.g., neuroblastoma, medullary thyroid cancer (MTC)). The incidence of NETs (2/100 000 for men and 2.4/100 000 for women) is believed to be higher than reported, primarily due to the substantial number of undetected and misclassified tumors (Kloppel et al. 2007, Modlin et al. 2008).

Since surgery is the only curative approach in NET, early detection and accurate staging of the disease are essential to establish the treatment and prognosis of the disease. Several imaging modalities are available for patients with a suspected NET such as anatomical imaging by computed tomography (CT) and magnetic resonance imaging (MRI) combined with functional whole-body imaging by scintigraphy with labeled analogues of somatostatin (SRS) and metaiodobenzylguanidine (MIBG). In addition, several recent studies have shown the usefulness of positron emission tomography (PET) in detection, characterization, and staging of NETs.

PET supplies a range of labeled compounds to be used for the characterization of tumor biochemistry. However, the most common tracer in PET imaging, $^{[18F]}$fluorodeoxyglucose ($^{[18F]}$FDG), is of limited value in the diagnosis of NETs expect for aggressive form of disease (Jadvar & Segall 1997, Adams et al. 1998, Pasquali et al. 1998). In this context, different tracers have been proposed to visualize NETs and the majority of these experiments have been based on the NET’s capacity to take up and decarboxylate amino acid precursors (APUDomas; Pearse 1969). For example, PET using radiolabeled amine precursors, such as hydroxytryptophan (HTP; Orlefors et al. 2005, Koopmans et al. 2008), hydroxyephedrine (Tramppel et al. 2004), dopamine (Pacak et al. 2001), and dihydroxyphenylalanine (DOPA), has been developed for the localization of NETs. Since the pioneering study of Ahlstrom et al. (1995) using carbon-11-labeled-DOPA, a fluorine-18-labeled analogue $^{[18F]}$DOPA has been used for the diagnosis of carcinoid tumors (Hoegerle et al. 2001b, Becherer et al. 2004, Koopmans et al. 2008), pheochromocytomas (Hoegerle et al. 2002, Timmers et al. 2007a), insulinomas (Otonkoski et al. 2006, Kauhanen et al. 2007, Koopmans et al. 2008), medullary thyroid carcinomas (Hoegerle et al. 2001a), and glomus tumors (Hoegerle et al. 2003).

Despite the promising results of $^{[18F]}$DOPA PET imaging in the diagnosis of NETs, it is not yet commonly used in the present clinical practice. The main goal of the study was to determine the added clinical value of $^{[18F]}$DOPA PET in a group of patients with different types of NET both in primary diagnosis and in staging and restaging of disease.

**Subjects and methods**

**Subjects**

We analyzed retrospectively the first 119 consecutive patients referred for $^{[18F]}$DOPA study to our national PET center between January 2000 and March 2007. Ten adult patients with surgically treated insulinoma and β-cell hyperplasia (Kauhanen et al. 2007), and 14 patients with CHI (congenital hyperinsulinism of infancy) (Otonkoski et al. 2006), have been reported before and were excluded from the analysis. Furthermore, ten additional patients, who underwent $^{[18F]}$DOPA PET for primary diagnosis and did not have biochemical proof of disease were excluded from the study. In three patients, complete data were not available, and therefore a total of 82 patients (37 males, 45 females, mean age: 40.5 ± 7.8 years) and 93 PET scans were included in the study. Depending on the indication for PET scanning, study patients were divided into 1) primary diagnosis and staging of disease and 2) restaging of disease. Ten of the study patients had a diagnosis of multiple endocrine neoplasia. The clinical characteristics, biochemical findings, reports of imaging studies, treatments, and follow-up examinations were recorded. The diagnostic accuracy of the PET studies was assessed by comparing the histopathological reports ($n = 30$) and clinical follow-up (mean: 17.3 ± 11.9 months, $n = 63$). Demographic data are given in Table 1. The data collection and analysis were approved by the Institutional Review Board.

**$^{[18F]}$DOPA PET-CT and PET technique**

Patientsfasted for at least 6 h before the PET scan. If the patient was on medication that could affect the biodistribution of $^{[18F]}$DOPA (diazoxide, somatostatin analogues, or cortisone), the medication was withdrawn 24 h before the study. In patients with suspicion of a pancreaticoduodenal NET, plasma glucose level was monitored and a glucose (G5–G10%, 40–100 ml/h) infusion was given, if needed, to keep the plasma glucose between 4.0 and 5.0 mmol/l.

The $^{[18F]}$DOPA PET scans were acquired using PET-CT (Discovery PET-CT; General Electric Medical Systems, Milwaukee, WI, USA; $n = 70$) and GE Advance (General Electric Medical Systems; $n = 33$) scanners. $^{[18F]}$DOPA PET was synthesized according to previously described methods (Bergman et al. 1994). The average administered dose of
PET images were analyzed visually and semi-quantitatively by calculating mean and maximum standardized uptake values (SUVs) defined as the ratio of activity per milliliter of tissue to the activity in the injected dose, corrected by decay and per patient’s body weight in the region of interest (ROI). ROIs were placed around the regions of increased DOPA uptake for $SUV_{\text{max}}$ and $SUV_{\text{mean}}$ determination. Any focal tracer accumulation exceeding normal regional tracer uptake was interpreted as a pathological finding. Whenever PET-CT was available, a clear uptake in the area where CT suggested bone fracture or degenerative bone lesions was not regarded as a positive finding.

**Other imaging studies**

All concurrent available conventional imaging studies (CT, MRI, SRS, MIBG scintigraphy) before 12 months (mean: 4.4 months, range: 0.5–12 months) of the PET scan were reviewed and catalogued. A total of 98 morphological imaging studies was available for comparison. Anatomical imaging with CT was performed on 75 patients and MRI on 23 patients. Some patients received additional functional imaging with SRS ($n=29$) and $[^{123}\text{I}]$MIBG scintigraphy ($n=5$) during their clinical workup.

**Data evaluation**

The diagnostic accuracy of the PET studies was assessed by comparing the histopathological reports ($n=30$) and the imaging findings. When the histology was not available, the consensus was based on the sum of the imaging procedures and follow-up examinations ($n=63$). Primary tumor site and axis were taken from the pathology reports if the patient had been operated, and otherwise from imaging studies. All the regions and lesions seen by different imaging modalities were calculated. If the number of lesions was over 10, the number of lesions was truncated at 11 lesions to avoid the bias toward that region.

**Statistical analysis**

The results are expressed mainly as means ± s.d. The specificity and sensitivity of PET for NET detection were calculated using the pathology results and the clinical follow-up as a gold standard using a $2 \times 2$ contingency table. A Mc Nemar test was performed to compare PET and combined CT/MRI ($n=83$) and SRS/MIBG scintigraphy ($n=35$) results, and $\kappa$ coefficient was determined to quantify agreement of these imaging methods. The Wilcoxon signed-rank test

---

**Table 1 Clinical features of patients studied by $[^{18}\text{F}]$DOPA scan ($n=93$)**

<table>
<thead>
<tr>
<th>Sex (male/female)</th>
<th>37/45</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age</td>
<td>40.5 ± 7.8</td>
</tr>
<tr>
<td>Indication of PET scanning</td>
<td></td>
</tr>
<tr>
<td>Primary diagnosis and staging ($n=32$)</td>
<td></td>
</tr>
<tr>
<td>Biochemical proof and clinical NET symptoms</td>
<td>23</td>
</tr>
<tr>
<td>Biochemical proof without clinical NET symptoms</td>
<td>9</td>
</tr>
<tr>
<td>Restaging ($n=61$)</td>
<td></td>
</tr>
<tr>
<td>F–U without biochemical proof</td>
<td>17</td>
</tr>
<tr>
<td>Standard F–U scan</td>
<td>8</td>
</tr>
<tr>
<td>Conventional imaging shows lesions</td>
<td>9</td>
</tr>
<tr>
<td>Biochemical proof and clinical NET symptoms</td>
<td>11</td>
</tr>
<tr>
<td>Biochemical proof without clinical NET symptoms</td>
<td>33</td>
</tr>
<tr>
<td>Chromogranin A nmol/l ($n=68$)</td>
<td>60.7 ± 157.9</td>
</tr>
<tr>
<td>Reference of final diagnosis</td>
<td></td>
</tr>
<tr>
<td>Histology</td>
<td>30</td>
</tr>
<tr>
<td>F–U</td>
<td>63</td>
</tr>
<tr>
<td>Mean F–U time (months)</td>
<td>17.3 ± 11.9</td>
</tr>
<tr>
<td>Primary treatment modality after PET</td>
<td></td>
</tr>
<tr>
<td>Surgery</td>
<td>30</td>
</tr>
<tr>
<td>Somatostatin analogues</td>
<td>11</td>
</tr>
<tr>
<td>Combined with chemo/radiation therapy</td>
<td>5</td>
</tr>
<tr>
<td>Chemoradiotherapy</td>
<td>4</td>
</tr>
<tr>
<td>Interferon-α</td>
<td>3</td>
</tr>
<tr>
<td>F–U without treatment</td>
<td>33</td>
</tr>
<tr>
<td>Other medical treatment</td>
<td>7</td>
</tr>
</tbody>
</table>

F–U, follow-up.

$[^{18}\text{F}]$DOPA was 234 ± 56 MBq. The decarboxylase inhibitor, carbidopa, was given in 19 patients as a premedication. Scanning began 60 min after tracer injection. Patients underwent a whole-body PET scan from the level of the eyes to the mid-thigh with a GE Advanced PET scanner operated in 2D mode, and after May 2005, scans were acquired on a combined PET-CT. This CT-based scan was used for attenuation correction purposes and to help in anatomic localization of DOPA uptake. Immediately after the CT, an emission PET scan was acquired in 3D mode over the same anatomical regions starting at the level of the mid-thigh.

To obtain images for visual and semi-quantitative analysis, the data were corrected for dead time, decay and photon attenuation, and reconstructed in a $128 \times 128$ matrix. The final in-plane resolution in segmented attenuation correction and iterative-reconstructed (SAC-OSEM) and Hann-filtered (4.6 mm) image was 5 mm (full-width half-maximum (FWHM)) when scanned with GE Advance. A fully 3D ML-OS-EM reconstruction algorithm (VuePoint) was used when scanning with PET-CT. The images were reconstructed using two iterations and 28 subsets with a 6.0 mm FWHM post-filter.
was used to evaluate the number of regions and lesions diagnosed by different imaging modalities. Fisher's exact test was used to test an association between symptoms and biochemical signs and PET findings. \( P < 0.05 \) was considered statistically significant. All statistical analyses were performed with SAS (version 8.2; SAS, Cary, NC, USA).

**Results**

**Clinical and endocrine status**

Patients were divided into five different study groups depending on the indication of PET scanning (Table 1). In primary diagnosis and staging, only patients with biochemical proof of disease were included, instead in restaging of known NET also patients with negative biochemistry were included \((n = 17)\). The serum chromogranin A (CgA) levels were significantly increased in 87% of the study patients with a mean level of 60.7 nmol/l \((n = 68)\) (normal value: \(< 4.0 \text{ nmol/l}\)). However, the serum level of CgA was not related to the distribution of positive or negative \([^{18}\text{F}]\text{DOPA PET findings} (P = 0.10)\). All the patients with primary suspicion of pheochromocytoma had elevated urinary metanephrine level with a mean value of 11.11 ± 15.28 \(\mu\text{mol/day}\) (normal value: 0.1–1.4 \(\mu\text{mol/day}\)), while normetanephrine values were normal (mean: 4.52 ± 3.65 \(\mu\text{mol/day}\), normal value: 0.5–4.2 \(\mu\text{mol}\)) \((n = 16)\). In all patients with recurrent MTC, calcitonin or carcinoembryonic antigen (CEA) was increased. The mean calcitonin level was 1418 ± 1830 pmol/l \((n = 13)\) (normal value: \(< 3.8 \text{ pmol/l for male, } < 1.7 \text{ pmol/l for female}\) and that of CEA was 186 ± 209 \(\mu\text{g/l} \) \((n = 11)\); normal value: \(< 5.0 \mu\text{g/l}\)). Patients with suspicion of pancreaticoduodenal NET had a fasting mean glucose level of 4.3 ± 3.9 mmol/l (normal value: \(< 2.5 \text{ mmol/l}\)), with concomitant insulin of 100.8 ± 156.4 mU/l (normal value: 5–20 mU/l), and C-peptide of 2.31 ± 3.48 nmol/l (normal value: 0.33–0.83 nmol/l). In the cases of ectopic ACTH syndrome, all patients had blunted suppression in 1 mg dexamethasone test (plasma cortisol: 1049 ± 480 nmol/l), and their serum ACTH concentration was 150 ± 221 ng/l (range: 29–640 ng/l). In restaging group, there was no significant association between the presence of symptoms and the biochemical proof of disease and sensitivity of \([^{18}\text{F}]\text{DOPA PET (P = 0.18 and 0.51 respectively).} \]

**\([^{18}\text{F}]\text{DOPA PET and conventional imaging}\)**

The results of imaging modalities in different indications are shown in Table 2. In 44 patients, \([^{18}\text{F}]\text{DOPA PET scans gave additional information compared with conventional imaging methods, and in another 11 patients PET gave information for the clinical diagnosis without conventional imaging methods. In addition, although 29 of the study patients had concordant findings in \([^{18}\text{F}]\text{DOPA PET and conventional imaging, PET gave more detailed information in diagnostically obscure patients with atypical symptoms and biochemical suspicion of the disease.} \]

Differences in classification between \([^{18}\text{F}]\text{DOPA PET and combined CT/MRI and SRS/MIBG were statistically significant (P = 0.009 and 0.003 respectively). The } \kappa \text{ coefficient for agreement was negative (} \kappa = -0.078) \text{ for [^{18}\text{F}]DOPA PET and CT/MRI, and that for [^{18}\text{F}]DOPA PET and SRS/MIBG scintigraphy was negligible (} \kappa = 0.202) \text{.} \]

In the analysis of 31 patients with advanced stage of disease, \([^{18}\text{F}]\text{DOPA PET detected significantly more affected regions (mean 2.7) and lesions (mean 5.0) compared with the combined results of CT and MRI (regions; mean 1.1, lesions; mean 1.7) (P < 0.001). Additionally, [^{18}\text{F}]DOPA PET detected a mean value of 0.9 regions and 1.9 lesions more than SRS and MIBG scintigraphy (n = 15) (regions, 3.0 vs 2.1; lesions, 5.5 vs 3.6) (Fig. 1).} \]

<table>
<thead>
<tr>
<th>Table 2 Results of different imaging modalities</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Search for primary and staging</strong></td>
</tr>
<tr>
<td>((n = 32))</td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td>([^{18}\text{F}]\text{DOPA PET (n = 93)})</td>
</tr>
<tr>
<td>CT ((n = 75))</td>
</tr>
<tr>
<td>MRI ((n = 23))</td>
</tr>
<tr>
<td>SRS/MIBGa(^a) ((n = 34))</td>
</tr>
</tbody>
</table>

TP, true-positive; TN, true-negative; FP, false-positive; FN, false-negative.

\(^a\)Five patients with suspicion of pheochromocytoma underwent MIBG scintigraphy.
Patients with positive biochemistry and negative conventional imaging

Thirty-five patients had positive biochemistry and negative conventional imaging and 32 of these patients had true-positive or -negative findings in PET scanning. In this patient group, [18F]DOPA PET had positive and negative predictive value of 0.92 and 0.95 respectively. When only patients with histological verification of disease were analyzed, a PPV of 1.00 (n = 8) and NPV of 0.67 (n = 3) were achieved. A mean number of different conventional imaging tests per patient was 1.46 ± 0.67 before referral for the PET scan.

Primary diagnosis and staging of NET

The distribution of indications and [18F]DOPA PET scan results are shown in Fig. 2. The accuracy of [18F]DOPA PET was 87% in patients having PET imaging for the primary diagnosis and staging of a NET (n = 32). The mean size of the primary tumors was 26 ± 11 mm. When assessing the organ-region-specific analysis, both the sensitivity and specificity for pheochromocytoma (n = 16) were 100%. Four out of five primary pheochromocytomas were located in left adrenals, and one in both adrenals in addition to metastatic lymph node in aorta bifurcation was identified in [18F]DOPA PET. An accuracy of 50% was achieved in the localization of primary tumors of the GI tract when pancreaticoduodenal tumors were excluded. Furthermore, the sensitivity and specificity in detecting primary pancreaticoduodenal NETs (n = 8) were 67% and 60% respectively. In six patients, [18F]DOPA PET scan was done for suspicion of ectopic ACTH-producing tumors, producing one true-positive and five true-negative findings.

Restaging of NET

Overall, 61 patients had [18F]DOPA PET for restaging of disease. The indications for [18F]DOPA PET imaging of restaging included suspicion of recurrence (n = 51) and follow-up studies (n = 10; Fig. 2). The overall accuracy of [18F]DOPA PET for restaging was 92%. In this group, [18F]DOPA PET detected advanced stage of disease in 31 patients (Fig. 3), while in four patients, the PET scan failed to detect metastasis partly (n = 2) or completely (n = 2). In restaging of disease, the accuracy was 89% for pheochromocytoma (n = 9) and 93% for a GI tract NET (n = 24). Furthermore, in tumors located in the head–neck–thoracic region (n = 19), the overall accuracy of [18F]DOPA PET was 89%, including 12 cases of recurrent MTC with a sensitivity and specificity of 90% and 100% respectively. The sizes of metastatic lesions were 16 ± 9 mm (range: 15–40 mm).

False-negative and false-positive findings

Overall, 9 out of 93 [18F]DOPA PET scans (10%) were considered either false negative (n = 6) or false positive (n = 3). In a subgroup analysis of six patients with false-negative finding in [18F]DOPA PET imaging, five out of six had advanced neuroendocrine carcinoma. In two of these patients, [18F]DOPA PET failed to show liver metastasis, and in one patient with metastasized NET, [18F]DOPA PET showed metastasis only in the mesenterium when CT showed additional lesions in the mediastinum and axillary regions, although histological verification of these lesions was missing. There were two additional patients where [18F]DOPA PET was not able to show metastasis in the neck region. Furthermore, only one benign form of NET, a 15 mm insulinoma in the head of the pancreas, was undetectable by [18F]DOPA PET.

In three cases, [18F]DOPA uptake in the PET scans was considered to be false positive. One patient with suspicion of paraganglioma recurrence had [18F]DOPA uptake in skeletal structures and in the right adrenal. Histological verification confirmed metastasis in the lumbar spine but a normal adrenal gland. One patient with strong suspicion of functional pancreatic NET had obscure diagnostic findings. He had two PET scans because of suspicion of insulinoma. Both the PET
scans showed accumulation of $[^{18}F]$DOPA in the head of the pancreas. The patient has been in follow-up with moderate symptoms for already 18 months since the second PET scan. Due to the lack of a histological diagnosis, the PET finding in this patient was considered a false-positive result.

**Discussion**

The present study indicates that $[^{18}F]$DOPA PET is a useful functional approach for diagnostic imaging of NETs with an overall accuracy of 90%. For the primary diagnosis and staging of clinically suspected NET, the $[^{18}F]$DOPA PET has an accuracy of 88% ($n = 32$) and 92% for restaging of disease ($n = 61$).

Furthermore, this retrospective series of 93 $[^{18}F]$DOPA PET scans in 82 patients showed that $[^{18}F]$DOPA PET imaging had an impact on the clinical management in 55 out of 93 (59%) cases and, additionally, confirmed the diagnosis in 29 obscure cases with inconclusive findings in conventional imaging. In a group of 35 patients with biochemical proof of disease and negative conventional imaging, $[^{18}F]$DOPA PET had high positive and negative predictive value of 92% and 95% respectively. Thus, our findings support the use of $[^{18}F]$DOPA PET scanning in the clinical workup of NET both in primary diagnosis and in staging and restaging of disease.

The localization of small primary of NETs is a challenge for diagnostic imaging. Furthermore, it is a
well-established fact that surgery is the only curative approach in both local and advanced NETs. Even in the case of metastasized disease, it has been shown that the cytoreductive resection of the tumor mass appears to be beneficial and may result in improved long-term recovery in a significant number of patients (Wright et al. 2007). Furthermore, the extent of tumor spread determines the type of oncological treatment. Thus, an accurate diagnostic tool is of crucial importance for both diagnostic purposes and in planning treatment of NETs.

Anatomical imaging (CT and MRI) (Maurea et al. 1993, Pacak et al. 2001) and functional imaging (SRS and MIBG scintigraphy) (Krenning et al. 1993) had limited sensitivity in the diagnosis of NET. Nowadays, SRS and MIBG scintigraphy are routine in patients with suspicion of a NET and its sensitivity exceeds that of CT and MRI (Krenning et al. 1993, van der Harst et al. 2001). SRS is based on the expression of somatostatin receptors in endocrine tumors and, therefore, the density of these receptors determines the efficacy of this imaging method. Besides the staging of disease, SRS is used to assess the efficacy of treatment with somatostatin analogue. However, SRS has low sensitivity in localizing small tumors lacking somatostatin receptor 2, which is the case in 20–50% of NETs (Reubi et al. 1994). Furthermore, the labeled catecholamine analogue MIBG is another well-established tracer for scintigraphy visualization. However, according to a recent review, up to 30% of carcinoid tumors had no accumulation of MIBG (Rufini et al. 2006), and scintigraphy seems to have limited sensitivity for the diagnosis of metastasized disease due to decreased expression of norepinephrine transporters by less differentiated cells. The sensitivity of MIBG scintigraphy was 57% in metastatic pheochromocytoma, and 92–96% in non-metastatic disease based on a series of 75 patients (van der Harst et al. 2001).

Initially, [18F]FDG was used as a tracer in PET imaging in the diagnosis of NETs. Accumulation of [18F]FDG in tumors is an index of increased glucose uptake, which reflects tumor aggressiveness, and, therefore, [18F]FDG PET is more sensitive in localizing metastatic NETs (Adams et al. 1998, Timmers et al. 2007b). In ectopic ACTH-secretting NETs, Pacak and co-workers, in a series of 17 patients, reported no advance in localizing tumors using [18F]FDG PET compared with conventional imaging (Pacak et al. 2004), whereas later on, one study reported successful localization of the disease in all three study patients (Kumar et al. 2006). Moreover, in localizing pheochromocytomas by [18F]FDG PET, the sensitivity was 70% for solitary benign or malignant disease (Shulkin et al. 1999). The lack of sensitivity of [18F]FDG PET in non-metastasized NET led to the studies of specifically targeted tracers that take advantage of the NET-specific catecholamine pathway. Based on the amine precursor uptake and

Figure 3 Fifty-seven-year-old female with abdominal pain imaged by CT, which revealed a 2 cm tumor in front of the inferior vena cava (arrow). (a) Fine needle biopsy of tumor indicated metastasis of NET, and therefore the patient was referred to [18F]DOPA PET-CT. In PET-CT, increased uptake of [18F]DOPA was detected in ileum (arrows) in addition to lymph node. (b–c) In operation, 2.7 cm primary tumor was resected from ileum (arrow) with a finding of lymph node. (d) Histological analysis confirmed NET with a proliferation index (Ki-67) of 5% and a metastatic lymph node.
decarboxylation systems of the NET, the amine precursor, l-DOPA, was introduced as a specific tracer to image these tumors (Ahlstrom et al. 1995).

The mechanism that determines the uptake of [18F]DOPA PET in neuroendocrine tissues is not fully understood. Increased activity of l-DOPA decarboxylase was found to be characteristic of NETs (Gazdar et al. 1988), probably contributing to tracer uptake (Gribil & Jensen 2004). The radiolabeled l-DOPA is transported across the membrane by an amino acid transporter, after which it is decarboxylated in [18F]fluoro-dopamine and stored in vesicles. Although [18F]DOPA PET was first synthesized several years ago, only a few studies of [18F]DOPA PET have been published so far. This might be due to the difficult labeling procedure.

Our results, especially the high sensitivity of 100% for 25 patients with suspected pheochromocytoma, are in concordance with the previous findings. Previously, only one small study using [18F]DOPA PET for the primary diagnosis of NET in 14 patients with pheochromocytoma with a sensitivity up to 100% has been published (Pacak et al. 2001, Hoegerle et al. 2002). Furthermore, Hoegerle and co-workers studied 17 patients with carcinoid tumors with a sensitivity of 65% for [18F]DOPA PET imaging compared with anatomical imaging with sensitivity of 73%. Although the anatomical imaging modalities were more sensitive in organ metastases, [18F]DOPA PET was better in the localization of primary tumors and lymph node metastases (Hoegerle et al. 2001b). Subsequently, other studies of advanced-stage carcinoids showed [18F]DOPA PET to be more sensitive than conventional imaging in detecting skeletal lesions (Becherer et al. 2004), and it also found more tumor lesions per region compared with combined SRS and CT (96 vs 65%; Koopmans et al. 2006). Our finding is in agreement with these previous studies, since we found that [18F]DOPA PET detected significantly more tumor lesions than combined CT/MRI imaging ($P<0.0001$). Recently, Montravers and co-workers concluded, in their study of 33 patients, that [18F]DOPA PET seems to be significantly more accurate in well-differentiated than in poorly differentiated NETs with an accuracy of 89% and 36% respectively (Montravers et al. 2006). Our results support this finding; when we analyzed the subgroup of patients with false-negative findings in [18F]DOPA PET imaging, five out of six patients had advanced neuroendocrine carcinoma.

There are also a few NET studies performed with other PET tracers. First, [11C]5-HTP, another amino acid precursor, has been successfully used in the diagnosis of NETs. The study by Orlefors reported that [11C]5-HTP PET could detect more tumor lesions than SRS and CT in 58% of the study patients (Orlefors et al. 2005). Moreover, a recent preliminary study showed that somatostatin analogue, [68Ga]DOTA-Tyr3-octreotide, is a promising new PET tracer in the diagnosis of NETs with a sensitivity of 97% and a specificity of 92% (Gabriel et al. 2007).

The main limitation of the present study was the lack of a pathological reference standard, although obtaining a biopsy specimen for histological verification from all participants with negative tests and several lesions is not feasible. Thus, we collected information during follow-up to confirm the true-positive and -negative findings. Another limitation is that conventional imaging studies, especially SRS and MIBG, were not performed systematically in all patients. The low accuracy of locating pancreatic NETs using [18F]DOPA PET is explained by the fact that the findings in ten patients with operatively treated insulinoma and β-cell hyperplasia have been published before with good results, and therefore were excluded from this report (Kauhanen et al. 2007). Furthermore, one argument concerning the use of [18F]DOPA in diagnosis suggests that non-functioning tumors may be difficult to detect, since accumulation reflects the secretion pattern of peptide hormones. However, the hypothesis that only amine-producing tumors can be imaged by [18F]DOPA PET has to be proved in further studies. According to our findings, even silent tumors without biochemical findings of a NET could be detected by [18F]DOPA PET.

Recently, several groups have suggested that inhibiting the peripheral decarboxylation can enhance tumor accumulation of HTP and DOPA. The decarboxylase inhibitor carbidopa, given as per oral premedication decreases the renal excretion and, at the same time, increases tumor uptake, hence improving visualization of the tumor (Eriksson et al. 2000, Orlefors et al. 2006, Timmers et al. 2007a). The physiological rather high uptake of the pancreas also disappears. In our institution, we have started to use premedication since May 2006 among NET patients except for pancreatic tumors. In this study, only 19 patients had premedication with carbidopa. The finding of increased sensitivity of [18F]DOPA PET after carbidopa is important and should be studied further with NETs of various organs. However, its routine use is not recommended with pancreatic tumors (except carcinoids) since pancreatic physiological uptake disappears, and it has not been confirmed that tumor uptake would not also disappear along with this (Kauhanen et al. 2008). Moreover, a further development has been combined PET-CT, which provides...
improved anatomical localization. In our study, 70 patients had combined PET-CT, although no statistical difference was observed between the accuracy of PET and PET-CT ($P=0.24$).

We have used [$^{18}$F]DOPA for almost a decade as a tracer in PET imaging of NETs. Our experiences are in accordance with the previous studies. However, all larger previous studies (Becherer et al. 2004, Hoegerle et al. 2001b, Koopmans et al. 2006, Montravers et al. 2006) included mostly patients with advanced NETs. To our knowledge, present study is the first to assess [$^{18}$F]DOPA PET in the primary diagnosis of NETs in various organs and our study is the largest reporting accurate diagnosis of pheochromocytoma using [$^{18}$F]DOPA PET, as well.

The main goal of the study was to analyze the clinical value of [$^{18}$F]DOPA PET in patients with suspicion of primary NET and positive biochemistry or restaging of disease. We conclude that in patients with a suspected NET but negative or inconclusive conventional imaging findings, [$^{18}$F]DOPA PET gives extremely useful information. This is especially true whenever pheochromocytoma is suspected. Furthermore, in patients with a formerly known NET and increasing tumor markers, [$^{18}$F]DOPA PET is a highly sensitive first-line imaging method in detecting a recurrent NET. Combined [$^{18}$F]DOPA PET-CT could be a one-step procedure not only in the staging of a NET but also in the primary diagnosis and follow-up.

Declaration of interest

The authors have nothing to disclose.

Funding

Financial support was provided by the National Graduate School of Clinical Investigation of Finland and a grant from Turku University Hospital (nr. 13018).

Acknowledgements

The authors thank Laura Nummijärvi, MSc, MB, for assistance with the data processing. We thank the staff of the Turku Cyclotron and the Radiochemistry Laboratory for technical support and advice, and the staff of the Turku PET Center for excellent help in imaging patients. We also thank the referring physicians and Irina Lisinen for consultation on the statistical analyses.

References


